Marshall Wace
MRVI icon

Marshall Wace’s Maravai LifeSciences MRVI Stock Holding History

Marshall Wace’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.89M Buy
2,081,334
+81,056
+4% +$275K 0.01% 1222
2025
Q4 		$6.5M Buy
2,000,278
+687,253
+52% +$2.31M 0.01% 1037
2025
Q3 		$3.77M Buy
1,313,025
+990,915
+308% +$2.53M ﹤0.01% 1314
2025
Q2 		$776K Sell
322,110
-71,902
-18% -$151K ﹤0.01% 1957
2025
Q1 		$871K Sell
394,012
-2,384,485
-86% -$9.42M ﹤0.01% 1849
2024
Q4 		$15.1M Buy
2,778,497
+2,763,072
+17,913% +$17.8M 0.02% 641
2024
Q3 		$128K Sell
15,425
-3,989,459
-100% -$34.5M ﹤0.01% 2347
2024
Q2 		$28.7M Sell
4,004,884
-824,862
-17% -$7.12M 0.04% 391
2024
Q1 		$41.9M Buy
4,829,746
+2,182,413
+82% +$14.8M 0.06% 295
2023
Q4 		$17.3M Buy
2,647,333
+1,889,796
+249% +$12.2M 0.03% 519
2023
Q3 		$7.58M Buy
757,537
+703,612
+1,305% +$7.73M 0.02% 736
2023
Q2 		$670K Sell
53,925
-1,699,014
-97% -$22.9M ﹤0.01% 1877
2023
Q1 		$24.6M Sell
1,752,939
-987,757
-36% -$14.2M 0.05% 394
2022
Q4 		$39.2M Buy
2,740,696
+663,660
+32% +$10.4M 0.09% 250
2022
Q3 		$53M Buy
2,077,036
+1,538,680
+286% +$38.6M 0.12% 179
2022
Q2 		$15.3M Buy
538,356
+37,144
+7% +$1.18M 0.03% 608
2022
Q1 		$17.7M Buy
501,212
+106,404
+27% +$3.57M 0.03% 548
2021
Q4 		$16.5M Sell
394,808
-1,093,208
-73% -$44.3M 0.03% 573
2021
Q3 		$73M Buy
1,488,016
+1,414,052
+1,912% +$69M 0.3% 47
2021
Q2 		$3.09M Sell
73,964
-163,221
-69% -$6.33M 0.01% 1128
2021
Q1 		$8.45M Sell
237,185
-125,795
-35% -$4.17M 0.04% 544
2020
Q4 		$10.2M Buy
+362,980
New +$10.1M 0.06% 344

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace's MRVI Position: Q1 2026 in Review

Marshall Wace increased its Maravai LifeSciences (MRVI) stake by 4.1% in Q1 2026, buying an estimated $275K and bringing the position to 2,081,334 shares worth $5.89M. The position accounts for 0.01% of the portfolio, ranked #1222.

Marshall Wace first reported a position in MRVI in Q4 2020 and has held it in 22 quarters since. The position peaked at $73M in Q3 2021. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Marshall Wace held 2,081,334 shares of Maravai LifeSciences worth $5.89M as of Q1 2026.
  • Marshall Wace bought 81,056 Maravai LifeSciences shares in Q1 2026, an estimated $275K.
  • Maravai LifeSciences made up 0.01% of Marshall Wace's portfolio in Q1 2026, its #1222 holding.
  • Marshall Wace first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 22 quarters since.
  • Marshall Wace's Maravai LifeSciences position peaked at $73M in Q3 2021.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.